Emerging therapies for atopic dermatitis: JAK inhibitors - 21/02/18

Doi : 10.1016/j.jaad.2017.12.019

David G. Cotter, MD, PhD, David Schairer, MD, Lawrence Eichenfield, MD ^⁎
Department of Dermatology and Department of Pediatrics, University of California, San Diego, and Rady Children's Hospital, San Diego, California

^∗Reprint requests: Lawrence Eichenfield, MD, Pediatric and Adolescent Dermatology, 8010 Frost St, Ste 602, San Diego, CA 92130.8010 Frost StSte 602San DiegoCA92130

Abstract

The Janus kinase–signal transducer and activator of transcription pathway is a conserved master regulator of immunity and myeloproliferation. Advanced understanding of this pathway has led to development of targeted inhibitors of Janus kinases (Jakinibs). As a class, JAK inhibitors effectively treat a multitude of hematologic and inflammatory diseases. Given such success, use of JAK inhibitors for mitigation of atopic dermatitis is under active investigation. Herein, we review the evolving data on the safety and efficacy of JAK inhibitors in treatment of atopic dermatitis. Although it is still early in the study of JAK inhibitors for atopic dermatitis, evidence identifies JAK inhibitors as effective alternatives to conventional therapies. Nonetheless, multiple large safety and efficacy trials are needed before widespread use of JAK inhibitors can be advocated for atopic dermatitis.

Le texte complet de cet article est disponible en PDF.

Key words : atopic dermatitis, baricitinib, eczema, JAK inhibitor, ruxolitinib, systemic therapy, tofacitinib

Abbreviations used : CPK, Cr, EASI, JAK, PASI, STAT

Plan

	Publication of this article was supported by Leo Pharma, Bayer, and Sanofi/Regeneron.
	Funding sources: Supported by Bayer, LEO Pharma, and Sanofi.
	Disclosure: Dr Eichenfield reports relevant financial relationships with Anacor, Pfizer, Leo Pharma, and Lilly. Drs Cotter and Schairer disclosed no conflicts of interest.